ALX Oncology Holdings Inc.

NASDAQ:ALXO

2.17 (USD) • At close September 19, 2024
Bedrijfsnaam ALX Oncology Holdings Inc.
Symbool ALXO
Munteenheid USD
Prijs 2.17
Beurswaarde 114,297,806
Dividendpercentage 0%
52-weken bereik 1.88 - 17.825
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jason W. Lettmann
Website https://www.alxoncology.com

An error occurred while fetching data.

Over ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's

Vergelijkbare Aandelen

Absci Corporation logo

Absci Corporation

ABSI

4.31 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.81 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

2.02 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

0.656 USD

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

3.45 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

6.57 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

4.35 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

9.18 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.465 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)